Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2-Dependent Mechanism

Journal of the American College of Cardiology

Volumn 55, Issue 10, 2010, Pages 1002-1006

  Liuni, Andrew ^a   Luca, Mary Clare ^a   Gori, Tommaso ^b   Parker, John D ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A reductase inhibitor; endothelium; ischemia reperfusion; rosuvastatin

Indexed keywords

CELECOXIB; CHOLESTEROL; CYCLOOXYGENASE 2; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; BLOOD VESSEL DIAMETER; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN EXPERIMENT; HYPEREMIA; ISCHEMIA; LIPOPROTEIN BLOOD LEVEL; NORMAL HUMAN; PRIORITY JOURNAL; RADIAL ARTERY; REPERFUSION INJURY; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADOLESCENT; ADULT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MODELS, CARDIOVASCULAR; MYOCARDIAL REPERFUSION INJURY; PREMEDICATION; PYRAZOLES; PYRIMIDINES; RADIAL ARTERY; SULFONAMIDES; VASODILATION; YOUNG ADULT;

EID: 77349096215     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.11.046     Document Type: Article

References (27)

1. Abela C.B., and Homer-Vanniasinkham S. Clinical implications of ischaemia-reperfusion injury. Pathophysiology 9 (2003) 229-240
2. Yellon D.M., and Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 357 (2007) 1121-1135
3. Laude K., Beauchamp P., Thuillez C., and Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res 55 (2002) 466-473
4. Vinten-Johansen J., Zhao Z.Q., Nakamura M., et al. Nitric oxide and the vascular endothelium in myocardial ischemia-reperfusion injury. Ann N Y Acad Sci 874 (1999) 354-370
5. Kharbanda R.K., Peters M., Walton B., et al. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 103 (2001) 1624-1630
6. Murry C.E., Jennings R.B., and Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74 (1986) 1124-1136
7. Yellon D.M., and Downey J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 83 (2003) 1113-1151
8. Jneid H., Leessar M., and Bolli R. Cardiac preconditioning during percutaneous coronary interventions. Cardiovasc Drugs Ther 19 (2005) 211-217
9. Gori T., Sicuro S., Dragoni S., Donati G., Forconi S., and Parker J.D. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation 111 (2005) 742-746
10. Gori T., Di Stolfo G., Sicuro S., et al. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol 64 (2007) 145-150
11. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., and Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res 942 (2002) 23-30
12. Naito Y., Katada K., Takagi T., et al. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. World J Gastroenterol 12 (2006) 2024-2030
13. Merla R., Daher I.N., Ye Y., Uretsky B.F., and Birnbaum Y. Pretreatment with statins may reduce cardiovascular morbidity and mortality after elective surgery and percutaneous coronary intervention: clinical evidence and possible underlying mechanisms. Am Heart J 154 (2007) 391-402
14. Ludman A., Venugopal V., Yellon D.M., and Hausenloy D.J. Statins and cardioprotection-more than just lipid lowering?. Pharmacol Ther 122 (2009) 30-43
15. Birnbaum Y., Ye Y., Rosanio S., et al. Prostaglandins mediate the cardioprotective effects of atorvastatin against ischemia-reperfusion injury. Cardiovasc Res 65 (2005) 345-355
16. Atar S., Ye Y., Lin Y., et al. Atorvastatin-induced cardioprotection is mediated by increasing inducible nitric oxide synthase and consequent S-nitrosylation of cyclooxygenase-2. Am J Physiol Heart Circ Physiol 290 (2006) H1960-H1968
17. Ye Y., Martinez J.D., Perez-Polo R.J., Lin Y., Uretsky B.F., and Birnbaum Y. The role of eNOS, iNOS, and NF-kappaB in upregulation and activation of cyclooxygenase-2 and infarct size reduction by atorvastatin. Am J Physiol Heart Circ Physiol 295 (2008) H343-H351
18. Bartoli G., Menegaz G., Lisi M., Di Stolfo G., Dragoni S., and Gori T. Model-based analysis of flow-mediated dilation and intima-media thickness. Int J Biomed Imaging 2008 (2008) 738545
19. Scalia R., Gooszen M.E., Jones S.P., et al. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103 (2001) 2598-2603
20. Jones S.P., Gibson M.F., Rimmer D.M., Gibson T.M., Sharp B.R., and Lefer D.J. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol 40 (2002) 1172-1178
21. Ikeda Y., Young L.H., and Lefer A.M. Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol 41 (2003) 649-656
22. Birnbaum Y., Ashitkov T., Uretsky B.F., Ballinger S., and Motamedi M. Reduction of infarct size by short-term pretreatment with atorvastatin. Cardiovasc Drugs Ther 17 (2003) 25-30
23. Sanada S., Asanuma H., Minamino T., et al. Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase. Circulation 110 (2004) 2143-2149
24. Mukherjee D., Nissen S.E., and Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286 (2001) 954-959
25. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
26. Juni P., Nartey L., Reichenbach S., Sterchi R., Dieppe P.A., and Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364 (2004) 2021-2029
27. Nugent A.G., McGurk C., McAuley D., Maguire S., Silke B., and Johnston G.D. Forearm reactive hyperaemia is not mediated by nitric oxide in healthy volunteers. Br J Clin Pharmacol 48 (1999) 457-459